


"Express Mail" Label No. EV 566969947
Date of Deposit November 28, 2005

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: 
Aaron Hokamura

Rec'd PCT/PTO 28 NOV 2005

PATENT

Attorney Docket No.: 082368-002810US
Client Reference No.: ONC-A0216P2-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Yusuke NAKAMURA et al.

Application No.: 10/529,381

Filed:

Int'l. Application No.: PCT/JP03/12074

Int'l Filing Date: September 22, 2003

For: GENES AND POLYPEPTIDES
RELATING TO PROSTATE CANCERS

Examiner:

Art Unit:

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

References AA through AI were cited in an International Search Report in a corresponding PCT application. A copy of this Search Report is also enclosed.


ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SR/

Reference AC is not in the English Language. An English language translation of the abstract is enclosed for the Examiner's review.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KLB:ath
60644832 v1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/529,381	
			Filing Date		
			First Named Inventor	Nakamura, Yusuke	
			Art Unit		
Examiner Name					
Sheet	1	of	2	Attorney Docket Number	082368-002810US

U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AA	WO	99/64631	A1	12-16-1999	Urocor, Inc.		<input type="checkbox"/>
	AB	WO	01/51628	A2	07-19-2001	Millenium Predictive Medicine, Inc.		<input type="checkbox"/>
	AC	JP	2002-010789 (with English abstract)	A	01-15-2002	Genset Corp.		<input checked="" type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. ⁶ If possible, Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/529,381	
			Filing Date		
			First Named Inventor	Nakamura, Yusuke	
			Art Unit		
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	082368-002810US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AD	EDWARDS, J.B.D.M. <i>et al.</i> ; "EST and encoded human protein"; <u>EMBL Database</u> ; September 20, 2002; Accession No. BD110979 (from JP 2002010789 A)	
	AE	LILLIE, J. <i>et al.</i> ; "Human breast cancer expressed polynucleotide 18890"; <u>EMBL Database</u> ; December 7, 2001; Accession No. AAL26433 (from WO 2001/051628 A2)	
	AF	LIN, Shi-Lung <i>et al.</i> ; "A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells"; <u>Biochem. Biophys. Res. Comm.</u> ; 2001; pp. 639-644; Vol. 281; Academic Press	
	AG	OHARA, O. <i>et al.</i> ; "Homo sapiens mRNA for KIAA0750 protein, complete cds"; <u>EMBL Database</u> ; November 17, 1998; Accession No. AB018293.	
	AH	SUZUKI, Takahiro <i>et al.</i> ; "MICAL, a novel CasL interacting molecule, associates with vimentin"; <u>J. Biol. Chem.</u> ; April 26, 2002; pp. 14933-14941; Vol. 277, No. 17	
	AI	TERMAN, Jonathan R. <i>et al.</i> ; "MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion"; <u>Cell</u> ; June 28, 2002; pp. 887-900; Vol. 109	

Examiner Signature	/Stephen Rawlings/	Date Considered	03/13/2008
--------------------	--------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.